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Tiivistelmä: 
Diabeetikot ovat alttiita jalkojen haavaumille, johtuen suureksi osaksi perifeerisestä 
neuropatiasta, heikentyneestä angiogeneesistä ja vähentyneestä granulaatiokudoksen 
muodostuksesta sekä myös heikentyneen solusignaloinnin ja heikentyneiden 
kasvutekijävasteiden johdosta. Tämä tutkimusraportti kuvaa hypoksian indusoima tekijä-1ɲ:n 
(Hypoxia Inducible Factor-1ɲ, HIF-1ɲ) sekä  verisuoniin hakeutuvan CAR-peptidin cDNA:n 
kloonausta  psectag2-vektoriin. Kloonaus suoritettiin, jotta voitaisiin tuottaa rekombinantti 
fuusioproteiini, jossa olisi liitettynä HIF-1ɲ:n ja CAR-peptidi. 
   Kloonaustrategiamme perustui haavojen verisuoniin hakeutuvaan CAR-peptidiin, joka on 
tunnistettu selomalla peptidikirjastoja (sisältäen 1x10Ͽ erilaista peptidiä). CAR-peptidi 
hakeutuu angiogeenisiin verisuoniin regeneroituvassa kudoksessa ja voi toimittaa siihen 
liitettyjä molekyylejä regeneroituvaan ihoon, luurankolihakseen ja jännehaavoihin jopa 200-
kertaisina pitoisuuksina verrattaessa kontroilleihin. Lisäksi CAR-peptidi on hyvin voimakas 
solukalvon läpäisevä peptidi, joka leviää vaurioituneissa kudoksissa ja läpäisee solukalvoja. On 
osoitettu, että CAR-peptidiin liitetyt molekyylit tai rekombinantit proteiinit voidaan toimittaa 
soluihin. 
  HIF-1 on suoraan happipitoisuuden säätelemä dimeerinen transkriptiotekijä, joka säätelee 
angiogeneesille tärkeiden geenien ekspressiota soluissa ja kudoksissa.  Jotta HIF-1ɲ voisi lisätä 
angiogeneesille tärkeiden kasvutekijöiden pitoisuutta kohdekudoksissa, sen täytyy päästä 
kudoksen solujen sisäpuolelle läpäisemällä solukalvot. 
   Tutkimusryhmämme tulee käyttämään CAR-peptidin haavan verisuoniin hakeutumista ja 
kudosläpäisevyyttä hyväksemme, tuottaaksemme fuusioproteiinin, jossa on liitettynä 
stabiloitu ja/tai lyhennetty muoto HIF-1ɲ:sta. 
  Kloonauksen jälkeen fuusioproteiinin templaatti-DNA:n sisältävä vektori lähetettiin 
proteiinituotantoa varten laboratorioon. 
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1. Aim of the study 
The purpose of this study was to produce a recombinant fusion protein consisting of 
mutated (constitutively active) version of the transcription factor Hypoxia inducible 
factor-1ɲ (HIF-1ɲ) and the vascular homing peptide CAR. This fusion protein could 
theoretically improve circulation and oxygen delivery to ischemic wounds in target 
organ specific fashion by inducing angiogenesis in the regenerating tissues. Mutated 
HIF-1ɲ has been shown to improve tissue perfusion in ischemic rabbit muscle using 
adenoviral delivery system (1).  
2. Review of the Literature 
2.1 Hypoxia inducible factor-1ɲ 
Hypoxia inducible factor-1ɲ (HIF-1ɲ) is one of the two proteins of the dimeric 
transcription factor HIF-1. HIF-1 is a heterodimer of HIF-1ɲ and HIF-1ɴ. The function of 
HIF-1 in cells is to trigger a cellular response and adaptation to hypoxia (low oxygen 
concentration). It achieves this by affecting the transcription of numerous genes that 
either help cells to survive in hypoxic conditions (adaptation) or increase the delivery 
of oxygen to the cellular environment by inducing formation of neovessels i.e. 
angiogenesis (homeostatic response). (2,3) 
    HIF-1 is a transcription factor that carries out its functions by up-regulating genes 
involved in cellular processes related to cellular survival in hypoxia, such as 
angiogenesis (vascular endothelial growth factor (VEGF), transforming growth factor-ɴ 
(TGF-ɴ)), cell growth and survival (insulin-like growth factor-2 (IGF-2), transforming 
growth factor-ɲ (TGF-ɲ)), glucose metabolism (lactate dehydrogenase A, 
phosphoglycerate kinase 1, glucose transporters (GLUTs) 1,3), erythropoiesis 
(erythropoietin), iron metabolism (ceruloplasmin, transferrin), matrix metabolism 
(matrix metalloproteinases) and  vascular tone (endothelin, heme oxygenase 1, nitric 
oxide synthase 2). (2,3) 
    HIF-1ɲ and HIF-1ɴ are both constitutively expressed and produced in all of our cells, 
but HIF-1ɲ is immediately degraded after its production in normoxic conditions. —The 
mechanism behind the rapid degradation of HIF-1ɲ is directly linked to oxygen; In 
normoxic conditions either one or both prolyl residues (amino acids 402 and 564) of 
HIF-1ɲ are hydroxylated by prolyl-4-hyroxylases (PHD-4). Prolyl-4-hydroxylases use 
oxygen and ɲ-ketoglutarate as substrates. This hydroxylation of prolyl residues allows 
the Von Hippel-Lindau (VHL) -tumor suppression protein to bind with HIF-1ɲ. VHL then 
recruits E3-ubiquitin-protein ligase, which, in turn, ubiquitinates HIF-1ɲ and directs it 
for proteosomal degradation inside the cells. Furthermore, the activity of HIF-1ɲ is also 
regulated by hydroxylation of asparagine residue 803 by factor inhibiting HIF-1 (FIH-1). 
This process inhibits binding of transcriptional co-activators CBP and p300 to HIF-1ɲ. 
(2,3) 
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Fig. 1. Activation of HIF-1 and mutated HIF-1ɲ (mHIF-1ɲ). In hypoxic conditions HIF-1ɲ is 
hydroxylated by prolyl-4-hydroxylases. This allows binding of Von Hippel-Lindau (VHL) tumor 
suppressor protein and results in ubiquination of HIF-1ɲ. Ubiquination directs HIF-1ɲ for 
proteosomal degradation.  
   In normoxic conditions HIF-1ɲ is not hydroxylated, binds with HIF-1ɴ and translocates into 
the nucleus. In the nucleus HIF-1 binds to genes that have hypoxia regulatory elements (HRE) 
in their promoter region and recruits coactivators such as CBP and p300. Formation of this 
complex induces expression of target genes. 
   mHIF-1ɲ has proline residues 402 and 564 mutated to alanine residues. This prevents 
hydroxylation by PHD1, PHD2 or PHD3 and binding of VHL. mHIF-1ɲ can bind with HIF-1ɴ and 
translocate to the nucleus. In the nucleus HIF-1 recruits coactivators and induces expression of 
target genes. Image modified from (2). 
   
     HIF-1ɲ is not degraded by above described mechanism in hypoxic conditions and 
can then bind and form heterodimers with HIF-1ɴ. The heterodimeric HIF-1 
translocates to the nucleus, where HIF-1 functions as a transcription factor for large 
number of its target genes. HIF-1 binds DNA and induces the transcription of genes 
involved in oxygen and vascular homeostasis (please see below). (2,3) 
HIF-1 regulates genes that contain the hypoxia response element (HRE) in their 
promoter region. These genes mediate a multitude of intracellular, paracrine and 
endocrine functions all aiming at providing survival in low oxygen conditions, i.e. in 
hypoxia. One group of HIF-1 target genes regulate cellular glucose metabolism. (2-5) 
 As a result of what is described above, mutation of prolyl residues 402 and 564 and 
the asparagine residue 803 to alanines could possibly stabilize HIF-1ɲ and thus, 
potentially provide HIF-1 driven constitutive transcriptional activity even in normoxic 
conditions. (1)  
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Fig. 2. Illustration of HIF-1ɲ and mutated HIF-1ɲ (mHIF-1ɲ) being regulated in hypoxic and 
normoxic conditions. Normoxia results in prolyl residues 402 and 564 of HIF-1ɲ being 
hydroxylated by PHD1, PHD2 or PHD3. Hydroxylation of these residues allows binding of Von 
Hippel-Lindau (VHL) tumor suppressor protein. VHL recruits a ubiquitin-protein ligase complex 
that ubiquinates HIF-1ɲ and directs it for proteosomal degradation. Factor inhibiting HIF-1 
hydroxylates asparagine residues within HIF-1ɲ which inhibits binding of coactivators and 
results in decreased activity. 
  During hypoxia activity of PHD1, PHD2, PHD3 and FIH are decreased which allows HIF1ɲ to 
bind with HIF1ɴ. HIF-1 then translocates into the nucleus and recruits transcriptional 
coactivators such as p300 and CBP.  This allows expression of target genes. 
   In normoxic conditions mHIF-1ɲ is not hydroxylated by PHD1,PHD2 or PHD3 and can 
therefore bind with HIF-1ɴ. HIF-1 then translocates to the nucleus and recruits coactivators 
such as CBP and p300 to form an active transcription factor. This transcription factor can 
induce expression of target genes. Image modified from (2). 
   
2.2 CAR-homing peptide 
The CAR wound-homing peptide (full sequence CARSKNKDC) was identified by in vivo 
phage display in the peptide library screen for peptides that home to angiogenic blood 
vessels in regenerating tissues. (6,7) 
    The CAR peptide has been shown to specifically bind to newly formed angiogenic 
blood vessels. This peptide has been shown to be capable of delivering systemically 
administered, therapeutic recombinant proteins, such as anti-fibrotic protein decorin 
(and human serum albumin), that are beneficial to wound healing, to wounds by 
targeting the cargo attached to CAR to angiogenic blood vessels being formed at the 
site of injury. (6,8). —Furthermore, the CAR peptide is a cell penetrating peptide that 
extravasates into the early granulation tissue, internalizes, and delivers cargo inside 
the cells (9). 
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    So far, it has been shown that the cell-penetrating CAR peptide is capable of 
delivering fluorescein, bacteriophage, extracellular matrix protein decorin and serum 
albumin into the nucleus of the cells (6,7,9). Thus, these properties make CAR peptide 
a plausible candidate to deliver transcription factors into the cells in target organ 
specific fashion  (6,7,9). 
 Fig. 3. Strategy for CAR-HIF-1D in diabetic wounds. HIF-1D will be expressed as a fusion 
protein with vascular targeting peptide CAR. CAR will deliver HIF-1D to the angiogenic 
vasculature forming at injured tissue, extravasate and penetrate into the cells. HIF-1D will turn 
on large number of angiogenic growth factors, such as VEGF and erythropoietin (EPO). B) 
Demonstration of CAR peptide being a potent cell penetrating peptide and C) extracellular 
protein decorin can be internalized into the CHO-K cells by CAR. 
2.3 Wound repair 
Wound repair can be divided to five phases: acute phase, inflammation, proliferation, 
maturation and remodeling. In the acute phase, a blood clot is formed and  growth 
factors and chemokines are released from extracellular matrix and intracellular 
vesicles in platelets. The inflammation phase begins after several hours and is 
characterized by extravasation and migration of neutrophiles, macrophages, 
endothelial cells and fibroblasts to the wound site. Especially the macrophages are 
involved in secreting additional growth factors that induce re-epithelialization, 
angiogenesis and fibroblast proliferation. In the proliferation phase, more cells migrate 
to the wound site and begin to proliferate. Fibroblasts in the wound site deposit new 
extracellular matrix. Collagen deposition is directly related to wound oxygen tension 
and perfusion. Maturation phase consists of resolution of cell proliferation and 
7 
 
 
extracellular matrix deposition as well as inflammation. In the remodeling phase, 
extracellular matrix and cells are reorganized to a stronger and more durable state and 
the scar formation takes place as an outcome of this process. (10) 
2.4 Diabetic ulcers 
There are over half a million diabetics in Finland. Diabetic patients are prone to foot 
problems caused by complications of diabetes: peripheral arterial disease (PAD) and 
peripheral neuropathy. About 9-23% of diabetic patients are estimated to have 
peripheral arterial disease.  Of diabetic foot ulcers 10% have only PAD as an etiologic 
factor and 50% ischemia together with peripheral neuropathy (11). The lifetime 
prevalence of foot ulcer in diabetics is 15% (12). 
   Wound healing in diabetes is impaired because of enzyme and protein dysfunction 
resulting from hyperglycemia, impaired oxygen delivery and disturbances in the 
immune system (10). 
Wound repair 
Acute phase                 
(minutes to hours) 
Inflammation                   
(hours to days) 
Proliferation                   
(days to weeks) 
Remodeling                    
(weeks to years) 
Disruption of vascular 
endothelium 
Arrival of inflammatory 
cells to wound site 
Proliferation of 
keratinocytes in wound 
edges and dermal 
appendages (e.g. hair 
follicles, sweat glands 
and sebaceous glands); 
re-epithelialization 
Equalization of collagen 
formation and 
degradation 
Extravasation of blood 
constituents 
Activation of monocytes 
to tissue macrophages 
Reorganization of 
deposited extracellular 
matrix 
Activation of platelets 
Release of additional 
cytokines and growth 
factors (e.g. 
transforming growth 
factor-ɴ, platelet 
derived growth factor, 
fibroblast growth factor, 
epidermal growth 
factor) by macrophages 
  Deposit of new 
extracellular matrix by 
fibroblasts i.e. 
Granulation 
Release of growth 
factors involved with 
chemotaxis, 
angiogenesis and re-
epithelialization 
  
Formation of new blood 
vessels (i.e. 
angiogenesis) 
  
  
Phagocytosis of debris, 
bacteria and breakdown 
tissue by 
polymorphonuclear 
neutrophils and 
macrophages 
Migration and 
proliferation of 
fibroblasts 
  
      
  
Release of vasodilative 
signaling 
molecules/inflammatory 
factors by macrophages 
    
      
Fig. 4. Phases of wound repair. 
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3. Materials and methods 
A full-length human mutated HIF-1ɲ (mHIF-1ɲ) cDNA was kindly provided by Dr. L. 
Poellinger (Karolinska Institute, Stockholm, Sweden). PCR of full length mHIF-1ɲ cDNA 
was performed using following primers; HifBamH1forw. (acgtggatccatggagg gcgccggcgg 
c) and HifEcoRIrev (gacgaattccgagccgttaacttgatccaaagc). Primer Tm was calculated 
using Finnzymes Tm calculator (http://www.thermoscientificbio.com/webtools/tmc/). 
The PCR product was purified with DNA purification kit (Qiagen, Venlo, Netherlands). 
The purified PCR product (after confirming the right size by gel electrophoresis) was 
digested using restriction enzymes BamH1 and EcoR1 (NEB, New England Biolabs, 
Cambridge, MA, USA). The digested product was purified using DNA purification kit 
(Qiagen, Venlo, Netherlands) according to protocol. 
      The pcDNA3.1/myc-his-C-expression vector (Invitrogen, Carlsbad, CA, USA) with 
following existing construct: BamH1 restriction site+decorin+EcoR1-restriction 
site+CAR-peptide+trombin cleavage site+HisTag (described previously in (8)) was 
digested with BamH1 and EcoR1 restriction enzymes to cut decorin cDNA out of the 
vector. The digested products were run on 1%-agarose gel with DNA-ladder and the 
band matching the right size (linear DNA) of EcoR1+CAR-peptide+thrombin cleavage 
site+HisTag in pcDNA3.1 was cut from gel and purified by DNA agarose gel extraction 
kit (Qiagen, Venlo, Netherlands) according to protocol. 
  mHIF-1ɲ PCR product was ligated to EcoR1+CAR-peptide+thrombin cleavage 
site+HisTag in pcDNA3.1 using T4 DNA ligase (NEB, New England Biolabs, Cambridge, 
MA, USA) according to overnight ligation protocol at 16 °C. Ligation product was used 
to transform One Shot TOP10F' Competent Cells (Invitrogen, Carlsbad, CA, USA) 
according to manufacturer's protocol. Cells were spread on LB agar ampicillin plates 
and plates were incubated overnight at 37 °C. Colonies from LB plates were selected 
for incubation at +37°C in LB (supplemented with ampicillin) medium. Glycerol stocks 
were made of incubated medium and vectors purified using Miniprep kit (Qiagen, 
Venlo, Netherlands).  
  Constructs were sequenced using following sequencing primers: T7 promoter 
(taatacgactcactataggg), BGH Reverse (tagaaggcacagtcgagg), Hif Seq sec 
1(cagaaatggcccagtgaga), Hif Seq sec 2 (gattttctcccttcaacaaacag), Hif Seq sec 3 
(aaaactgtttgctgaagacacaga). Primers were chosen 400 base pairs apart from each other 
to cover the whole construct. The OligoPerfect™ Designer 
(https://tools.lifetechnologies.com/content.cfm?pageid=9716&icid=fr-oligo-6?CID=fl-
oligoperfect) was used for their optimal design. 
   PCR of mHIF-1ɲ+CAR-peptide+thrombin cleavage site+HisTag-construct was 
performed using primers HifSfiIforw. (ggcccagccggcc gagggcgccggcggcgag) and  
HisTagXhoIrev (tctagactcgagttagtgatggtg).  The PCR-product was purified using DNA 
purification kit according to protocol (Qiagen, Venlo, Netherlands).  The purified PCR 
product was  digested (after confirming right size with gel electrophoresis) with 
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restriction enzymes SfiI and XhoI (NEB, New England Biolabs, Cambridge, MA, USA). 
The digested product was purified using DNA purification kit according to protocol 
(Qiagen, Venlo, Netherlands). 
     pSecTag2-vector (Invitrogen, Carlsbad, CA, USA) was digested with  restriction 
enzymes SfiI and XhoI (NEB, New England Biolabs, Cambridge, MA, USA). Digestion 
with SfiI and XhoI cut out most of restriction sites in the multiple cloning site of 
pSecTag2. The reaction solution ran on 1%-agarose gel with DNA ladder. The band 
consistent with the size of the linearized, digested vector was cut from gel and purified 
using agarose gel extraction kit according to the manufacturer´s protocol (Qiagen, 
Venlo, Netherlands).  
     HIF-1ɲ+CAR-peptide+thrombin cleavage site+HisTag-construct was ligated to 
psectag2-vector using T4 DNA-ligase (NEB, New England Biolabs, Cambridge, MA, USA) 
according to overnight ligation protocol. Ligation product was used to transform One 
Shot TOP10F' Competent Cells (Invitrogen, Carlsbad, CA, USA).  Cells were spread on LB 
ampicillin-agarose plates and plates were incubated overnight at +37°C. Colonies were 
selected for incubation at +37°C in LB-ampicillin medium. After incubation glycerol 
stocks were made of incubated medium and minipreps were made using Miniprep kit 
(Qiagen, Venlo, Netherlands). Products were sequenced using sequencing primers 
described above. 
HIF-1ɲ+CAR-peptide+thrombin cleavage site+HisTag-construct in psectag2-vector was 
sent for protein production in mammalian cells. 
Figure 5. Schematic representation of domain structure of CAR-HIF-1D-cDNA fusion 
construct. NTAD  (N-terminal transactivation domain); CTAD ( C-terminal transactivation 
domain); NLS ( nuclear localisation signal). See text for description. 
4. Results 
Sequencing confirmed the cloning product to be consistent with the insert HIF-
ϭɲ+CAR+Trombin cleavage site+HisTag bein incorporated into psectag2-vector. The 
construct was sent for protein production in baculovirus expression system. 
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Figure 6. Production of recombinant CAR-HIF-1D fusion proteins in the baculovirus system. 
The recombinant protein was expressed in baculovirus expression system, purified on a Ni-
NTA-column, separated on gradient SDS-PAGE gels. (A) SDS-PAGE gel was stained by 
Coomassie. (B) Western blot analysis: proteins were transferred to nitrocellulose membrane 
and detected with a monoclonal anti-6-histidine tag antibody. E1 – E6 eluates after the 
purification; C –positive control; sup - supernatant from uninfected culture. 
5. Discussion 
Diabetic wounds are difficult and expensive to treat. They result from protein and 
enzyme dysfunction that is caused by hyperglycemia, impaired oxygen delivery (caused 
by micro- and macrovascular changes) and disturbances in the immune system. (10) 
Diabetic foot is also more susceptible to trauma because of peripheral neuropathy 
caused by diabetes (11).  Improving oxygen delivery to diabetic wounds could improve 
wound healing and reduce the number of patients with chronic wounds, wound 
infections and amputations in diabetics.  
    Gene therapy with mHIF-1ɲ delivered by adenoviral transfection vector has been 
shown to improve wound healing in a rabbit ischemic muscle model (1). As a master 
gene switch for angiogenic program HIF-1 can upregulate multiple genes involved with 
angiogenesis (2). A mutated HIF-1ɲ and CAR-peptide fusion protein should accumulate 
in the newly formed blood vessels in the wound and potentially improve wound 
healing by stimulating angiogenesis and improving oxygen delivery.   
   Recombinant HIF-1 has been successfully produced in bacterial cells (13).  Our aim is 
to produce HIF-1 coupled to wound homing and cell penetrating peptide CAR in 
baculovirus essentially in the same fashion as described in E.coli by Van de Sluis (13). In 
addition to full-length HIF-1D (1-826), we will generate following variants; short form 
of HIF-1D (1-390) (14,15), as the truncated version of HIF-1D has been more active 
than the native, full-length HIF-1D and has been used in clinical gene therapy-trials in 
humans (14,15). The latter will consist of the native DNA-binding and dimerisation 
subunits of the HIF-1D, but is devoid of the natural transactivation domains, which are 
replaced by either one of the two independent, strong, oxygen-independent, 
constitutively active transactivation domains; 1) herpes simplex virus VP16 
transactivation domain (16) or 2) 11 tandem copies of FDTDL, a minimal, critical region 
from a very potent transactivation domain of ɴ-catenin (17). Both VP16 and 
[FDTDL]x11 have been used successfully for similar outcome and have been shown to 
provide stronger transactivating domains than the native HIF-1D transactivation 
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domains does (16,17). CAR will be juxtaposed to the transactivation domain after a 
short flexible linker (Fig. 6). In addition of being more active than the native HIF-1D, 
the truncated CAR-HIF-1D fusion-protein should be substantially smaller than the full-
length protein. We anticipate that, the probability of robust protein production in 
native conditions is increased substantially by this reduction in size of the recombinant 
protein. 
      With recombinant CAR- vascular homing peptide fused to HIF-1ɲ, we hope to 
deliver HIF-1ɲ inside of cells in wounds in target organ specific fashion. After 
internalization of the recombinant protein to the cells by the cell penetrating 
capabilities of CAR, the recombinant mHIF-1ɲ can dimerize with HIF-1ɴ and translocate 
into the nucleus. Inside the nucleus HIF-1 will induce transcription of target genes e.g. 
VEGF. With this, we hope to stimulate angiogenesis and improve oxygen delivery and  
ultimately the outcome of wound healing in diabetic patients in disease-specific 
fashion. 
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 7. Supplemental material 
HIF1ɲ+CAR+Thrombin cleavage site+HisTag sequence 
AGAGGGCGCCGGCGGCGAGAACGAGAAGAAAAATAGG 
ATGAGTTCTGAACGTCGAAAAGAAAAGTCTAGAGATGCAGCAAGATCTCGGCGAAGCAAAGA
GTCTGAAG 
TTTTTTATGAGCTTGCTCATCAGTTGCCACTTCCCCACAATGTGAGCTCACATCTTGATAAAGCT
TCTGT 
TATGAGGCTCACCATCAGTTATTTACGTGTGAGAAAACTTCTGGATGCCGGTGGTCTAGACAG
TGAAGAT 
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GAGATGAAGGCACAGATGGACTGTTTTTATCTGAAAGCCCTAGATGGCTTTGTGATGGTGCTA
ACAGATG 
ACGGCGACATGGTTTACATTTCTGATAACGTGAACAAATACATGGGGTTAACTCAGTTTGAAC
TAGCTGG 
ACACAGTGTGTTTGATTTTACTCATCCATGTGACCATGAGGAAATGAGAGAAATGCTTACACA
CAGAAAT 
GGCCCAGTGAGAAAAGGGAAAGAACTAAACACACAGCGGAGCTTTTTTCTCAGAATGAAGTG
CACCCTAACAAGCCGGGGGAGGACGATGAACATCAAGTCAGCAACGTGGAAGGTGCTTCACT
GC 
ACGGGCCATATTCATGTCTATGATACCAACAGTAACCAACCTCAGTGTGGGTACAAGAAACCA
CCCATGA 
CGTGCTTGGTGCTGATTTGTGAACCCATTCCTCATCCGTCAAATATTGAAATTCCTTTAGATAG
CAAGAC 
ATTTCTCAGTCGACACAGCCTCGATATGAAATTTTCTTACTGTGATGAAAGAATTACTGAGTTG
ATGGGT 
TATGAGCCGGAAGAACTTTTGGGCCGCTCAATTTATGAATATTATCATGCTTTGGATTCTGATC
ATCTGA 
CCAAAACTCACCATGATATGTTTACTAAAGGACAAGTCACCACAGGACAGTACAGGATGCTTG
CCAAAAG 
AGGTGGATATGTCTGGGTTGAAACTCAAGCAACTGTCATATATAATACGAAGAACTCCCAGCC
ACAGTGC 
ATTGTGTGTGTGAATTATGTTGTAAGTGGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACA
AACAG 
AATCTGTGCTCAAACCAGTTGAATCTTCAGATATGAAGATGACTCAGCTGTTCACCAAAGTTGA
ATCAGA 
GGATACAAGCTGCCTTTTTGATAAGCTTAAGAAGGAGCCTGATGCTCTCACTCTGCTGGCTGC
AGCTGCC 
GGCGACACCATCATCTCTCTGGATTTTGGCAGCGATGACACAGAAACTGAAGATCAACAACTT
GAAGATG 
TTCCATTATATAATGATGTAATGTTTCCCTCTTCTAATGAAAAATTAAATATAAACCTGGCAATG
TCTCC 
TTTACCTTCATCGGAAACTCCAAAGCCACTTCGAAGTAGCGCTGATCCTGCACTGAATCAAGA
GGTTGCA 
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TTAAAATTAGAATCAAGTCCAGAGTCACTGGGACTTTCTTTTACCATGCCCCAGATTCAAGATC
AGCCAG 
CAAGTCCTTCTGATGGAAGCACTAGACAAAGTTCACCTGAG---
CCTAACAGTCCCAGTGAATATTGCTTTGA 
TGTGGATAGCGATATGGTCAATGTATTCAAGTTGGAACTGGTGGAAAAACTGTTTGCTGAAG
ACACAGAG 
GCAAAGAATCCATTTTCAACTCAGGACACTGATTTAGATTTGGAGATGCTGGCTGCCTATATCC
CAATGG 
ATGATGATTTCCAGTTACGTTCCTTTGATCAGTTGTCACCATTAGAGAGCAATTCTCCAAGCCC
TCCAAG 
TATGAGCACAGTTACTGGGTTCCAGCAGACCCAGTTACAGAAACCTACCATCACTGCCACTGC
CACCACA 
ACTGCCACCACTGATGAATCAAAAACAGAGACGAAGGACAATAAAGAAGATATTAAAATACT
GATTGCAT 
CTCCATCTTCTACCCAAGTACCTCAAGAAACGACCACTGCTAAGGCATCAGCATACAGTGGCA
CTCACAG 
TCGGACAGCCTCACCAGACAGAGCAGGAAAGAGAGTCATAGAACAGACAGACAAAGCTCATC
CAAGGAGC 
CTTAACCTGTCTGCCACTTTGAATCAAAGAAATACTGTTCCTGAGGAAGAATTAAACCCAAAG
ACAATAG 
CTTCGCAGAATGCTCAGAGGAAGCGAAAAATGGAACATGATGGCTCCCTTTTTCAAGCAGCA
GGAATTGG 
AACATTATTGCAGCAACCAGGCGACTGTGCACCTACTATGTCACTTTCCTGGAAACGAGTGAA
AGGATTC 
ATATCTAGTGAACAGAATGGAACGGAGCAAAAGACTATTATTTTAATACCCTCCGATTTAGCA
TGCAGAC 
TGCTGGGGCAGTCAATGGATGTGAGTGGATTACCACAGCTGACCAGTTACGATTGTGAAGTT
AATGCTCC 
CATACAAGGCAGCAGAAACCTACTGCAGGGTGAAGAATTACTCAGAGCTTTGGATCAAGTTA
ACGGCTCG 
GAATTCTGTGCACGTTCGAAGAACAAAGATTGCGTCGACCTGGTGCCGCGCGGCAGCTCGCA
TCACCATC 
ACCATCACTAACTCGAG 
15 
 
 
 
Protein sequence 
E G A G G E N E K K N R Met S S E R R K E K S R D A A R S R R S K E S E V F Y E L A H Q L P 
L P H N V S S H L D K A S V Met R L T I S Y L R V R K L L D A G G L D S E D E Met K A Q Met 
D C F Y L K A L D G F V Met V L T D D G D Met V Y I S D N V N K Y Met G L T Q F E L A G H 
S V F D F T H P C D H E E Met R E Met L T H R N G P V R K G K E L N T Q R S F F L R Met K 
C T L T S R G R T Met N I K S A T W K V L H C T G H I H V Y D T N S N Q P Q C G Y K K P P 
Met T C L V L I C E P I P H P S N I E I P L D S K T F L S R H S L D Met K F S Y C D E R I T E L 
Met G Y E P E E L L G R S I Y E Y Y H A L D S D H L T K T H H D Met F T K G Q V T T G Q Y R 
Met L A K R G G Y V W V E T Q A T V I Y N T K N S Q P Q C I V C V N Y V V S G I I Q H D L I 
F S L Q Q T E S V L K P V E S S D Met K Met T Q L F T K V E S E D T S C L F D K L K K E P D A 
L T L L A A A A G D T I I S L D F G S D D T E T E D Q Q L E D V P L Y N D V Met F P S S N E K 
L N I N L A Met S P L P S S E T P K P L R S S A D P A L N Q E V A L K L E S S P E S L G L S F T 
Met P Q I Q D Q P A S P S D G S T R Q S S P E P N S P S E Y C F D V D S D Met V N V F K L 
E L V E K L F A E D T E A K N P F S T Q D T D L D L E Met L A A Y I P Met D D D F Q L R S F 
D Q L S P L E S N S P S P P S Met S T V T G F Q Q T Q L Q K P T I T A T A T T T A T T D E S K 
T E T K D N K E D I K I L I A S P S S T Q V P Q E T T T A K A S A Y S G T H S R T A S P D R A G 
K R V I E Q T D K A H P R S L N L S A T L N Q R N T V P E E E L N P K T I A S Q N A Q R K R K 
Met E H D G S L F Q A A G I G T L L Q Q P G D C A P T Met S L S W K R V K G F I S S E Q N 
G T E Q K T I I L I P S D L A C R L L G Q S Met D V S G L P Q L T S Y D C E V N A P I Q G S R 
N L L Q G E E L L R A L D Q V N G S E F C A R S K N K D C V D L V P R G S S H H H H H H 
Stop 
 
